Other Mutations: GD1/2

NCT04842812: Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

NCT04842812
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2, Mesothelin+, MUC1, GPC3, LeY, AXL, EGFR, ROR1+, GD1/2, B7-H3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 85 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT04842812

NCT00445965: Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: GD1/2
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain, Leptomeningeal disease
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT00445965

Up ↑